ArticleMolecular cancer therapeutics2021
Gilteritinib Inhibits Glutamine Uptake and Utilization in
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 44 citations in OpenAlex.
- Unraveling the role of glutamine metabolism in cancer: from cell death mechanisms to tumor microenvironment modulation.Experimental hematology & oncology · 2026Review
- Targeting oncogenic FLT3 uncovers a ferroptosis vulnerability through selenocysteine recoding in acute myeloid leukaemia.Nature cell biology · 2026Article
- Lactate metabolism and epigenetic reprogramming drive c-KIT hyperactivation to mediate Gilteritinib resistance: Rationale for c-KIT degraders over kinase inhibitors.Acta pharmaceutica Sinica. B · 2026Article
- A case of intestinal tumor formation during gilteritinib therapy that resolved without discontinuing the drug.Clinical journal of gastroenterology · 2026Article
- Article
- Targeting the Glutaminolysis Pathway in Glaucoma-Associated Fibrosis.International journal of molecular sciences · 2025Review
- Amino acid metabolic reprogramming drives pathogenesis and therapy in hematologic malignancies.Discover oncology · 2025Review
- Impact of physiological media on acute myeloid leukemia bioenergetics and cell proliferation.Cancer & metabolism · 2025Article
- Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.Therapeutic advances in drug safety · 2025Article
- Feasibility and Safety of Targeting Mitochondria Function and Metabolism in Acute Myeloid Leukemia.Current pharmacology reports · 2024Article
- Glutamine and leukemia research: progress and clinical prospects.Discover oncology · 2024Review
- Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling.Cell reports. Medicine · 2024Article
- XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.Annals of hematology · 2024Article
- SLC25A51 decouples the mitochondrial NADCell metabolism · 2024Article
- Potentiating Gilteritinib Efficacy Using Nanocomplexation with a Hyaluronic Acid-Epigallocatechin Gallate Conjugate.Polymers · 2024Article
- TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.Leukemia · 2024Article
- Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy.Scientific reports · 2023Article
- Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect.Annals of hematology · 2023Article
- Ionizing radiation-induced mitophagy promotes ferroptosis by increasing intracellular free fatty acids.Cell death and differentiation · 2023Article
- Targeting Glutamine Metabolism as an Attractive Therapeutic Strategy for Acute Myeloid Leukemia.Current treatment options in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Megan E Zavorka ThomasDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Xiyuan LuDepartment of Nutritional Sciences and Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, Texas.
Zahra TalebiDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Jae Yoon JeonDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Daelynn R BuelowDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Alice A GibsonDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.ORCID 0000-0001-5910-5067
Muhammad Erfan UddinDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.ORCID 0000-0002-7160-0455
Lindsey T BrintonDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
Julie NguyenDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia.ORCID 0000-0002-4928-8012
Meghan CollinsDepartment of Nutritional Sciences and Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0002-6201-9298
Alessia LodiDepartment of Nutritional Sciences and Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, Texas.
Shannon R SweeneyDepartment of Nutritional Sciences and Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0001-7080-8716
Moray J CampbellDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.ORCID 0000-0002-3355-0928
Douglas H SweetDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia.ORCID 0000-0002-8911-9184
Alex SparreboomDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Rosa LapalombellaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
Stefano TizianiDepartment of Nutritional Sciences and Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0002-7230-0307
Sharyn D BakerDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio. baker.2480@osu.edu.
The Ohio State University · USThe University of Texas at Austin · USVirginia Commonwealth University · US
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MTyrosine kinase inhibitors for the treatment of childhood AMLR01CA138744 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SHARYN D · 2010 to 2019
$3.3MTherapeutic targeting of glutamine metabolism in MDSR01CA206210 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y, TIZIANI, STEFANO · 2016 to 2020
$2.4MNCI NIH HHS P30 CA016058NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA138744NCI NIH HHS R01 CA206210
Abstract
Acute myeloid leukemia (AML) with an
Indexed as
Aniline CompoundsAnimalsFemalefms-Like Tyrosine Kinase 3GlutamineHumansLeukemia, Myeloid, AcuteMicePyrazinesAniline CompoundsFLT3 protein, humanfms-Like Tyrosine Kinase 3gilteritinibGlutaminePyrazines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.